Ascendis Health Limited (JSE:ASC)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc 96.00
0.00 (0.00%)
Nov 21, 2025, 11:28 AM SAST
Ascendis Health Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
600.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 1.47B | -63.39M | -4.13% |
| Jun 30, 2023 | 1.54B | -24.02M | -1.54% |
| Jun 30, 2022 | 1.56B | -266.01M | -14.57% |
| Jun 30, 2021 | 1.83B | -377.56M | -17.14% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clicks Group | 47.83B |
| Aspen Pharmacare Holdings | 43.36B |
| Dis-Chem Pharmacies | 40.88B |
| Life Healthcare Group Holdings | 26.73B |
| Netcare | 25.85B |
| AfroCentric Investment Corporation | 8.48B |
| Labat Africa | 199.40M |
Ascendis Health News
- 9 days ago - Ascendis (ASND) Q3 2025 Earnings Call Transcript - The Motley Fool
- 6 weeks ago - Ascendis submits application to market TransCon CNP in EU - Seeking Alpha
- 2 months ago - Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ... - GuruFocus
- 3 months ago - Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade - Seeking Alpha
- 3 months ago - Ascendis (ASND) Q2 2025 Earnings Call Transcript - The Motley Fool
- 4 months ago - Ascendis wins FDA approval for growth hormone deficiency treatment - Seeking Alpha
- 6 months ago - Ascendis rises after FDA priority review for genetic condition treatment - Seeking Alpha
- 6 months ago - Ascendis highlights long-term efficacy of Yorvipath for hypoparathyroidism - Seeking Alpha